Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
Delayed Japan Exchange  -  12:22 2022-10-04 am EDT
1964.00 JPY   +2.19%
10/03Astellas Files Marketing Application in Europe for Menopause Medication
MT
09/30European Medicines Agency Accepts Astellas Marketing Authorization Application for Fezolinetant
AQ
09/29European Medicines Agency Accepts Astellas Pharma Inc. Marketing Authorization Application for Fezolinetant
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma Inc. Announces Executive Changes

08/02/2022 | 12:08am EDT

Astellas Pharma Inc. announced that Dr. Tadaaki Taniguchi, MD, Ph.D, will be appointed to the new Chief Medical Officer (CMO) as of October 1, 2022. He joined Astellas as Executive Advisor on July 1, 2022. He is an internationally trained surgeon in the field of oncology with extensive industry experience in developing and commercializing innovative medicines as a senior leader in major global pharmaceutical companies.

He will be based in the US. Bernhardt Zeiher, M.D., the current CMO, will retire on September 30, 2022. As of Ocober 1, 2022, the name of Chief Administrative Officer and Chief Ethics & Compliance Officer (CAO & CECO) will be renamed to the Chief People Officer and Chief Ethics & Compliance Officer (CPO & CECO).

With the growing focus on human capital in corporate management, the change signifies this position's leadership role in transforming human resources and the organization as a whole. Katsuyoshi Sugita will be appointed to CPO & CECO as of October 1, 2022. He has held senior HR leadership positions in the pharmaceutical and technology industries and joined Astellas as Head of Human Resources in May 2021.

Since joining Astellas, Mr. Sugita has leveraged his extensive experience and expertise in the area of Human Resources to promote innovation and the active participation of human resources toward the realization of the Organizational Health Goals. Fumiaki Sakurai, the current CAO & CECO, will retire on September 30, 2022. Name: Tadaaki Taniguchi, Career History.

July 2022 Executive Adviser, Astellas Pharma Inc. (present post) December 2021 SVP, Head of Oncology Business Unit Asia Strategy, AstraZeneca PLC November 2019 SVP, Head of Global Medical Affairs, Oncology Business Unit, AstraZeneca PLC January 2019 SVP, Head of Research & Development Japan, AstraZeneca K.K. April 2015 Vice President, Head of Japan Research & Development, Global Medicine Development, AstraZeneca K.K. December 2012 Vice President, Head of Japan Research & Development, Bristol-Myers Squibb K.K. October 2011 Executive Director and Strategic Officer, China Development, MSD China March 2006 Executive Director, Clinical Sciences, Deputy Head of Japan Development, MSD K.K. January 2004 Senior Director, Clinical Research, Deputy Head of Clinical Development Institute, Banyu Pharmaceutical Co. Ltd. March 2000 Research Director, Clinical Development Institute, Banyu Pharmaceutical Co. Ltd. November 1996 Clinical Research Fellow, Molecular Pathology Unit, Imperial Cancer Research Fund, Hammersmith Hospital, London.

June 1991 Surgical Resident, Tokyo Metropolitan Oncology and Infectious Disease Center Hospital. Name: Katsuyoshi Sugita, Career History May 2021 EVP, Human Resources Head, Astellas Pharma Inc. (present post) July 2016 Head of Human Resources, Microsoft Japan Co. Ltd. August 2012 Head of Human Resources, AstraZeneca K.K. November 2008 Head of Human Resources, Hilti Japan Ltd. September 2003 Johnson & Johnson K.K. April 2002 ITOCHU Techno-Solutions Corp.

April 1991 Asahi Kasei Corp.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
ACCENT GROUP LIMITED 5.71% 1.3425 Delayed Quote.-47.76%
ASTELLAS PHARMA INC. 2.16% 1964 Delayed Quote.2.49%
All news about ASTELLAS PHARMA INC.
10/03Astellas Files Marketing Application in Europe for Menopause Medication
MT
09/30European Medicines Agency Accepts Astellas Marketing Authorization Application for Fezo..
AQ
09/29European Medicines Agency Accepts Astellas Pharma Inc. Marketing Authorization Applicat..
CI
09/29Lupin Gets US FDA Nod for Overactive Bladder Drug
MT
09/29ASTELLAS PHARMA INC. : Ex-dividend day for interim dividend
FA
09/27US Court Temporarily Bars US Drugmaker Hospira from Launching Generic Version of Astell..
MT
09/20Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start..
AQ
09/12Seagen, Merck, Astellas Release Data From Trial of Padcev, Keytruda to Treat Bladder Ca..
MT
09/12Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV(R) (..
CI
09/04Astellas Pharma Inc. Announces Topline Results from Phase 3 Long-Term Safety Study of F..
CI
More news
Financials
Sales 2023 1 454 B 10 077 M 10 077 M
Net income 2023 206 B 1 427 M 1 427 M
Net cash 2023 395 B 2 738 M 2 738 M
P/E ratio 2023 16,9x
Yield 2023 3,12%
Capitalization 3 503 B 24 272 M 24 272 M
EV / Sales 2023 2,14x
EV / Sales 2024 1,95x
Nbr of Employees 14 522
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 1 922,00 JPY
Average target price 2 596,15 JPY
Spread / Average Target 35,1%
EPS Revisions
Managers and Directors
Kenji Yasukawa Chairman, President & Chief Executive Officer
Minoru Kikuoka Chief Financial Officer
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.2.49%24 272
JOHNSON & JOHNSON-4.60%429 503
ELI LILLY AND COMPANY17.06%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.25%245 597
ABBVIE INC.-0.88%237 296